Ranbaxy Laboratories' recall of generic Lipitor has spawned its first legal repercussion. A New Jersey man has sued the Indian generics maker, Pharmalot reports, questioning why it took two weeks for the company to publicly notify consumers that they might be getting ground glass with their cholesterol-lowering medicine. The lawsuit points out that even then, there was only a small notice on its U.S. website. The FDA followed up with a national announcement of the voluntary recall of the 41 lots. Ranbaxy has since stopped manufacturing the pills in the affected doses while it figures out whether the discovery of glass in a raw material can be tracked to a missing piece of glass from a machinery shield or some other explanation. Story | More